Enacting the right to try for individualized treatments act to permit a manufacturer to make an individualized investigative treatment available to a requesting patient.

SB 250 allows manufacturers to provide personalized experimental treatments based on a patient's genetic profile to individuals with life-threatening or severely debilitating illnesses who have exhausted all FDA-approved options. It requires patients to receive detailed written consent from their physician outlining treatment options, risks, and financial responsibilities, and mandates that patients cover costs unless the manufacturer agrees otherwise. The bill explicitly states manufacturers aren't required to provide treatments, insurers aren't obligated to cover them, and patients bear all costs - including potential liability for unpaid expenses. It also requires patient consent for any commercial use of their biological samples and clarifies that this law doesn't alter existing insurance coverage requirements.